Skip to main content

SurpassMD vs Remedy Meds: Flat Low Pricing vs Premium Access

By the Peptide Dossier Editorial TeamUpdated How we source

Peptide Dossier and SurpassMD share ownership. We receive no referral fee or commission. Read our ownership disclosure.

SurpassMD offers compounded semaglutide as low as $114/month and tirzepatide as low as $177/month, flat across every dose, with cold shipping within 48 hours of approval, oral semaglutide and nutrition guidance. Remedy Meds emphasizes unlimited clinician visits and messaging, monthly check-ins and cancel-anytime service. Its current homepage also advertises shipping within 48 hours. The distinction is the care bundle and billing structure, not an assumed delivery-speed or price winner.

Advertised Plans and Services: October 28, 2026

Advertised provider plans and services checked October 28, 2026
FeatureSurpassMDRemedy Meds
SemaglutideAs low as $114/mo; flatCurrent product-specific quote not stated in reviewed public pages
TirzepatideAs low as $177/mo; flatCurrent product-specific quote not stated in reviewed public pages
Dose escalationFlat — no increase with doseHelp center: same base subscription amount regardless of dose
Oral optionOral semaglutide; needle-freeReviewed homepage focuses on injected GLP-1 plans
Brand-name optionNoneOzempic and Zepbound advertised; separate quote
Provider accessAsync review + supportUnlimited clinician visits/video + messaging
BillingCancel anytime; as-low-as longest-subscription rateAutomatic renewal every 28 days; refill form required
PaymentCash-pay; HSA/FSA & KlarnaHomepage advertises HSA/FSA acceptance
ShippingCold, within 48 hours of approvalHomepage advertises shipping within 48 hours
Regulatory historyNew brand (2026)September 9, 2025 FDA marketing/misbranding letter
Coverage50 states + DCEligibility depends on service and clinician availability

Pricing, Access and 28-Day Billing

Remedy’s billing guidance says subscriptions renew every 28 days and a refill form is required before the next shipment. Its public pages reviewed October 28 did not establish a current product-specific dollar quote, so no current dollar-price ranking is assigned here. SurpassMD’s $114/$177 flat offers provide the stated price reference here. If changing platforms, the receiving clinician decides whether to prescribe, which formulation to use and whether the previous dose remains appropriate; continuing that dose is not guaranteed. For another view of care options, our GLP-1 Program Guide helps readers compare telehealth programs.

Frequent access can be useful when you want clinician contact during treatment changes or side-effect management. Both the prescribed product and the individual assessment matter. Read GLP-1 side effects and how long semaglutide side effects last for symptom context.

Verdict: Which Should You Choose?

Choose SurpassMD for its stated flat prices, no dose-based increase, oral semaglutide, nutrition guidance and 48-hour dispatch. Choose Remedy when you value its unlimited clinician access and 28-day service model. Its September 9, 2025 FDA letter concerns misleading product-equivalence marketing; it is not a product-testing finding that every shipment was unsafe. Current pricing and the payment interval should be compared before enrollment.

Full reviews: SurpassMD review and Remedy Meds review. See the ranked best GLP-1 telehealth providers and the full price comparison.

Frequently Asked Questions

SurpassMD advertises semaglutide as low as $114/month and tirzepatide as low as $177/month, flat across doses. The current Remedy public pages reviewed here did not state a product-specific dollar quote, so this comparison does not assign a current saving. Remedy’s help center says billing repeats every 28 days; that interval must be aligned before comparing annual totals.

A higher current Remedy price is not established without a current product-specific quote. Remedy advertises unlimited clinician visits and messaging between check-ins, monthly plan review and pharmacy fulfillment. Its homepage also lists brand-name Ozempic and Zepbound, without a verified current price in the pages reviewed here. Those access and product options are useful when you expect to use frequent clinician support.

Yes. The FDA’s September 9, 2025 letter cited misleading compounded semaglutide and tirzepatide claims that implied equivalence to approved products. It explains that compounded products are not FDA-approved. The letter addresses marketing and misbranding; it does not provide laboratory findings about every dispensed product or certify present compliance.

No. SurpassMD’s as-low-as $114/month semaglutide and $177/month tirzepatide offers stay flat across all doses; the rate reflects the longest subscription option and is cancel-anytime. Remedy also states in its help center that its base subscription amount does not increase with dosage, with the amount tied to the selected subscription.

Both advertise shipping within 48 hours; SurpassMD’s stated clock begins at provider approval. Remedy’s homepage says shipping within 48 hours and recurring pharmacy fulfillment every 28 days. These are dispatch/service statements, not proof of the same delivery date. SurpassMD’s advertised offer includes cold shipping to all 50 states plus DC, HSA/FSA and Klarna options, and nutrition guidance.

Choose SurpassMD for the stated flat $114/$177 offers, oral semaglutide, nutrition guidance and 48-hour cold dispatch. Choose Remedy if unlimited clinician contact is the priority. A new platform performs its own clinical assessment before deciding on a product or dose.

Compounded medications are not FDA-approved or reviewed for safety, effectiveness, or quality. A prescription is never guaranteed; eligibility is determined by an independent licensed provider.